GILD News 96.16 10/16/2014 05:03:54 Gilead Sciences (GILD)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Gilead Sciences (GILD) 96.16 $GILD

Final Glance: Biotechnology companies
AP - Wed Oct 15, 5:07PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 96.16 (-1.02), AMGN: 130.90 (-1.30), CELG: 86.55 (+0.07)

Novavax Begins Mid-Stage Study on RSV Vaccine in Elders - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 4:20PM CDT
Novavax (NVAX) initiates phase II study on RSV vaccine.
MDVN: 89.63 (-1.68), EBS: 20.89 (+0.97), GILD: 96.16 (-1.02), NVAX: 4.69 (+0.20)

Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 12:59PM CDT
Will Gilead's new HCV combo treatment pick up share like Sovaldi and bring in multi-billion dollar sales for the company?
VRTX: 101.10 (-3.16), ALNY: 84.39 (+1.44), GILD: 96.16 (-1.02), SRPT: 20.91 (+2.00), AUXL: 30.41 (-0.46), AMGN: 130.90 (-1.30), ABBV: 54.63 (+0.50)

Midday Glance: Biotechnology companies
AP - Wed Oct 15, 12:17PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 96.16 (-1.02), AMGN: 130.90 (-1.30), CELG: 86.55 (+0.07)

Should Gilead Sciences, inc. Fear Incoming Competition?
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 15, 12:17PM CDT
Gilead Sciences ' shares have tumbled more than 8% in the past week as investors digest the FDA approval of its second-generation hepatitis C drug Harvoni and the potential competitive threats from AbbVie and Bristol-Myers Squibb . ...
GILD: 96.16 (-1.02), ABBV: 54.63 (+0.50), BMY: 48.96 (+0.04)

Healthcare ETFs in Focus on JNJ Earnings Beat - ETF News And Commentary
Sweta Killa - ZACKS - Wed Oct 15, 12:00PM CDT
Investors should take a close look to healthcare ETFs following Johnson & Johnson earnings beat.
JNJ: 98.21 (+1.20), PPH: 58.58 (-1.27), IYH: 127.08 (-0.84), GILD: 96.16 (-1.02), ABBV: 54.63 (+0.50), XLV: 60.52 (-0.50)

Jim Cramer on Stocks and Investing: Why I Hate This Market
at The Street - Wed Oct 15, 10:21AM CDT
Because it’s completely hit or miss.
JNJ: 98.21 (+1.20), SWKS: 49.60 (+0.69), GILD: 96.16 (-1.02), DOW: 44.09 (+0.16)

Early Glance: Biotechnology companies
AP - Wed Oct 15, 9:46AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 96.16 (-1.02), AMGN: 130.90 (-1.30), CELG: 86.55 (+0.07)

Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths
at The Street - Wed Oct 15, 8:35AM CDT
Some perspective on recent positive news, which nonetheless, caused Seattle Genetics and Gilead shares to fall.
SGEN: 33.33 (+1.37), GILD: 96.16 (-1.02)

Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver
PR Newswire - Wed Oct 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, TKMR, GILD, DDD and TASR.
TSLA: 229.70 (+2.64), GILD: 96.16 (-1.02), DDD: 41.27 (+0.25), TKMR: 23.90 (+0.30), TASR: 14.69 (+0.49)

'Fast Money' Recap: Now May Be the Time to Buy Energy Stocks
at The Street - Wed Oct 15, 4:00AM CDT
The trading panel discussed whether margin calls are weighing on the energy sector and which technology stocks to consider.
F: 13.62 (-0.16), SWKS: 49.60 (+0.69), AMGN: 130.90 (-1.30), SOXX: 76.42 (+0.36), INTC: 31.27 (-0.87), PANW: 97.43 (+3.18), JNPR: 19.13 (+0.36), COH: 35.54 (-0.08), EBAY: 50.24 (-0.35), GILD: 96.16 (-1.02), GWPH: 61.55 (-3.65), DPZ: 83.65 (-0.65), GOOGL: 540.73 (-7.96), CP: 187.12 (-1.57), MELI: 106.16 (-1.87), CSCO: 22.96 (-0.10), KING: 11.38 (+0.13)

J&J raises outlook on Q3 beat
at Investor's Business Daily - Tue Oct 14, 5:51PM CDT
The medical giant's earnings, ex items, rose 10% to $1.50 a share, beating analysts' estimates by 5 cents. Sales climbed 5% to $18.47 bil, $90 mil ahead of consensus. Johnson & Johnson (JNJ) raised its full-year EPS guidance to $5.92-$5.97, on the...
JNJ: 98.21 (+1.20), GILD: 96.16 (-1.02)

Gilead
at Investor's Business Daily - Tue Oct 14, 5:49PM CDT
Gilead (GILD) shares fell 4.2% to 97.18 as light sales of J&J's Olysio could imply that Sovaldi sales may also come in light. Comments by J&J executives that they will work to make Olysio accessible and competitive in light of the recent approval of...
GILD: 96.16 (-1.02)

Wall Street Ends Mixed; Airlines Soar As Oil Plunges
at Investor's Business Daily - Tue Oct 14, 4:09PM CDT
Stocks ended mixed Tuesday after trimming early gains. Volume crept higher. The Nasdaq rose 0.3%, the S&P 500 climbed 0.2%, and the Dow Jones industrial average slipped a fraction. Preliminary data showed that volume rose slightly on the NYSE and the...
NFLX: 448.59 (-0.53), SWKS: 49.60 (+0.69), GILD: 96.16 (-1.02), DAL: 32.38 (-0.41), DPZ: 83.65 (-0.65), BAC: 15.76 (-0.76), SCHW: 25.32 (+0.04), URI: 93.43 (+0.98), LUV: 30.02 (+0.02)

Citigroup and Domino's are big market movers
AP - Tue Oct 14, 3:38PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
CERS: 4.21 (+0.11), HD: 87.85 (-2.25), ATLS: 37.45 (+2.15), C: 49.68 (-1.79), CSX: 32.98 (+0.37), AWI: 45.72 (-0.33), JNJ: 98.21 (+1.20), ALCS: 0.41 (+0.03), AES: 12.84 (-0.37), JPM: 55.53 (-2.46), GILD: 96.16 (-1.02), AAL: 31.69 (+0.18), DPZ: 83.65 (-0.65), STO: 23.42 (-0.58), OUTR: 55.54 (+1.92)

Stocks Close Mixed, Surrendering Some Early Gains
at Investor's Business Daily - Tue Oct 14, 3:23PM CDT
Stocks could only manage a mixed close Tuesday after surrendering significant gains. The Nasdaq and S&P 500 rose 0.3% and 0.2%, respectively, while the Dow Jones industrial average closed down a fraction. Preliminary numbers show volume tracking...
LCI: 40.30 (-0.36), GILD: 96.16 (-1.02), ALXN: 160.73 (+1.27), CVX: 109.27 (-0.51)

Stocks Retain Gains As Market Finally Gets A Rally
at Investor's Business Daily - Tue Oct 14, 1:55PM CDT
Stocks held on to much of their gains going into the final hour of trading Tuesday en route to finishing up for the first day in four. The Nasdaq rose 0.5%; the S&P 500 climbed 0.4%; and the Dow Jones industrial average gained 0.3%. Volume was...
SWKS: 49.60 (+0.69), GILD: 96.16 (-1.02), C: 49.68 (-1.79), DPZ: 83.65 (-0.65), ATHM: 45.12 (+2.63)

Drug Analysts Mull End Of 'Double Irish' Loophole
at Investor's Business Daily - Tue Oct 14, 12:10PM CDT
Wall Street was scrambling to assess the impact on drug stocks of the closing of a tax loophole known as "double Irish," proposed by the Irish government Tuesday. The issue is a different one from the overall lower corporate tax rates in Ireland,...
ACT: 217.24 (-4.83), GILD: 96.16 (-1.02), LLY: 62.87 (-0.27)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 101

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 79

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Sungrow Puts Storage Safety and Deployment on Display

Updated Category News Views 129

Fire-test footage is not usually the thing that grabs a room in Las Vegas, but Sungrow made it the centerpiece at RE+ 2026 for a reason. Energy storage has no shortage of glossy promises; what it needs is proof that equipment can handle the ugly stuff. Sungrow used the show to pitch a broader North American lineup, yet the PowerTitan 3.0 battery system and its large-scale...

Continue Reading
V2’s FOAS Bets on Candid Ad Sales Operator Dialogue

Updated Category News Views 99

Ad sales rarely gets fixed by another ballroom panel, and V2 seems to know it. Its new Future of Ad Sales, or FOAS, forum is built around a simpler premise: put senior operators in a small room, keep vendors and conference theatrics out of the way, and let people compare the ugly real-world details of running revenue machines. Announced November 19, 2026, FOAS is an...

Continue Reading
Vanguard's Digital Win Matters More Than a Trophy

Updated Category News Views 104

A wealth manager’s website rarely earns applause, but a bad one can sure as hell lose trust fast. Vanguard’s move to No. 1 from No. 3 in the 2025 ranking for advised-investor website satisfaction is worth noticing because it hits the unglamorous part of wealth management that clients actually live with: checking accounts, understanding a plan, moving cash, and...

Continue Reading
Envision’s COP31 Pitch Hinges on Grid Execution, Not Targets

Updated Category News Views 93

A 2,500 GW traffic jam is a rotten place to park climate ambition. Envision Energy used COP31 in Antalya to make the more useful point: clean-power targets mean very little if grids cannot connect, balance and dispatch the electricity. Kane Xu’s message was not another round of flag-waving promises. It was an argument that the constraint has shifted from wanting...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 33

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 218

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
Tigerlily Takes Its Advocacy Model to Ovarian Cancer

Updated Category News Views 136

Ovarian cancer has a nasty habit of hiding behind symptoms people are taught to shrug off. Persistent bloating or pelvic pain can look like any number of ordinary problems, and that ambiguity is exactly why practical, trusted education matters. Tigerlily Foundation's new ovarian cancer initiative is not a flashy breakthrough claim. It is a grounded attempt to help women...

Continue Reading
Mindgruve's Tech Hire Puts Sightline Growth in Focus

Updated Category News Views 23

Agency technology hires usually land with all the thunder of a stapler dropping, but this one deserves a closer look. Mindgruve has named Steve Terjeson vice president of technology, handing a former WPP Choreograph executive the job of leading its software development and data engineering teams. The assignment is not vague: push AI innovation, make the proprietary...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating 15 Years of Animal Rescue Corps' Impact

Updated Category News Views 307

Animal Rescue Corps Commemorates 15 Years of Impact Animal Rescue Corps (ARC), a dedicated national nonprofit organization, is excited to celebrate 15 remarkable years of rescuing animals and advocating for their protection. This milestone is not just a reflection of the past but a commitment to continue fighting for animals in need. To honor this achievement, ARC warmly...

Continue Reading
Investigating Investor Claims: Atara Biotherapeutics Update

Updated Category News Views 184

Investor Investigations into Atara Biotherapeutics Recent developments have led to significant interest from investors regarding Atara Biotherapeutics, Inc. (NASDAQ: ATRA). Allegations of possible securities fraud have prompted Pomerantz LLP to investigate the circumstances surrounding the company's practices. If you hold shares in Atara, it's crucial to stay informed...

Continue Reading
Systech's Remarkable 40-Year Journey in Pharma Packaging

Updated Category News Views 329

Systech Celebrates 40 Years of Industry Excellence Marking four decades of innovation, Systech has emerged as a key player in the field of packaging and serialization for the pharmaceutical industry. The company has developed a unique platform that alleviates the common frustrations of working with multiple vendors, providing a comprehensive solution that enhances...

Continue Reading
Empowering Black Artists: The BMAC LIVE Accelerator Initiative

Updated Category News Views 134

The Black Music Action Coalition Launches BMAC LIVE Accelerator Program The Black Music Action Coalition (BMAC) has officially announced the exciting return of its BMAC LIVE Accelerator Program. This initiative is designed to empower Black artists and professionals in the music industry by providing essential resources, training, and mentorship opportunities. BMAC...

Continue Reading
Imperial Petroleum Announces Series A Preferred Share Dividend

Updated Category News Views 212

Imperial Petroleum Inc. Declares Dividend on Series A Preferred Shares ATHENS, Greece – Imperial Petroleum Inc. (NASDAQ: IMPP), a prominent player in the maritime shipping industry, recently made headlines with the announcement of a dividend of $0.546875 per share on its 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock. This dividend is notably payable to...

Continue Reading